

AMENDMENT

Listing of the claims:

1. (Currently amended) A method for treating inflammation in an animal having inflammation caused by one or more of immune-mediated inflammation, osteoarthritis, rheumatoid arthritis, glomerulonephritis, colitis, or cystitis, comprising administering to the animal an effective amount of a composition comprising:

- (a) a mycobacterial deoxyribonucleic acid obtained from a disrupted mycobacterium, the mycobacterial deoxyribonucleic acid preserved and complexed on a mycobacterial cell wall (BCC); and
- (b) a pharmaceutically acceptable carrier, wherein the amount is effective to treat the inflammation.

2. (Currently amended) A method for preventing inflammation in an animal, comprising administering to the animal at risk of inflammation from immune-mediated inflammation, osteoarthritis, rheumatoid arthritis, glomerulonephritis, colitis, or cystitis, an effective amount of a composition comprising:

- (a) a mycobacterial deoxyribonucleic acid obtained from a disrupted mycobacterium, the mycobacterial deoxyribonucleic acid preserved and complexed on a mycobacterial cell wall (BCC); and
- (b) a pharmaceutically acceptable carrier, wherein the amount is effective to prevent the inflammation.

3-10. Previously cancelled

11. (Originally presented) The method of Claim 1, wherein the effective amount is effective to induce the synthesis of cytokine IL-10.
12. (Originally presented) The method of Claim 2, wherein the effective amount is effective to induce the synthesis of cytokine IL-10.
13. (Originally presented) The method of Claim 1, wherein the pharmaceutically acceptable carrier is selected from the group consisting of a liquid carrier and a solid carrier.
14. (Originally presented) The method of Claim 2, wherein the pharmaceutically acceptable carrier is selected from the group consisting of a liquid carrier and a solid carrier.
16. (Originally presented) A method for treating inflammation in an animal having inflammation, comprising administering to the animal an effective amount of a composition comprising *Mycobacterium phlei*-DNA preserved and complexed on a *Mycobacterium phlei* cell wall (MCC) and a pharmaceutically acceptable carrier, wherein the amount is effective to prevent the inflammation.
17. (Originally presented) A method for preventing inflammation in an animal, comprising administering to the animal an effective amount of a composition comprising *Mycobacterium phlei*-DNA preserved and complexed on a *Mycobacterium phlei* cell wall

(MCC) and a pharmaceutically acceptable carrier, wherein the amount is effective to prevent the inflammation.

18. (Originally presented) The method of Claim 16, wherein the effective amount is effective to induce the synthesis of cytokine IL-10.

19. (Originally presented) The method of Claim 17, wherein the effective amount is effective to induce the synthesis of cytokine IL-10.

20. (Originally presented) The method of Claim 16, wherein the pharmaceutically acceptable carrier is selected from the group consisting of a liquid carrier and a solid carrier.

21. (Originally presented) The method of Claim 17, wherein the pharmaceutically acceptable carrier is selected from the group consisting of a liquid carrier and a solid carrier.

22. (Newly presented) A method for treating inflammation in an animal having inflammation, comprising administering to the animal an effective amount of a composition comprising a mycobacterial deoxyribonucleic acid preserved and complexed on a mycobacterial cell wall (BCC) and a pharmaceutically acceptable carrier, wherein the amount is effective to induce the synthesis of cytokine IL-10 and treat the inflammation.

23. (Newly presented) A method for preventing inflammation in an animal, comprising administering to the animal an effective amount of a composition comprising a

mycobacterial deoxyribonucleic acid preserved and complexed on a mycobacterial cell wall (BCC) and a pharmaceutically acceptable carrier, wherein the amount is effective to induce the synthesis of cytokine IL-10 and prevent the inflammation.

24. (Newly presented) The method of Claim 1, wherein the mycobacterial deoxyribonucleic acid and the mycobacterial cell wall are obtained from *Mycobacterium phlei*.

25. (Newly presented) The method of Claim 2, wherein the mycobacterial deoxyribonucleic acid and the mycobacterial cell wall are obtained from *Mycobacterium phlei*.

26. (Newly presented) The method of Claim 22, wherein the mycobacterial deoxyribonucleic acid and the mycobacterial cell wall are obtained from *Mycobacterium phlei*.

27. (Newly presented) The method of Claim 23, wherein the mycobacterial deoxyribonucleic acid and the mycobacterial cell wall are obtained from *Mycobacterium phlei*.